Vizsgálati helyszín
Mount Vernon Cancer Centre
Northwood, Middlesex HA6 2RN, Egyesült KirályságMég nincs intézményhez kötve
- 17futó vizsgálat
- 9lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 26 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis2 vizsgálat
- 1. fázis1 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Toboroz9 vizsgálat
- Fut, nem toboroz8 vizsgálat
- Lezárult8 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Amgen3 vizsgálat
- Janssen Research & Development, LLC3 vizsgálat
- EMD Serono Research & Development Institute, Inc.2 vizsgálat
- AVEO Pharmaceuticals, Inc.1 vizsgálat
- Cambridge University Hospitals NHS Foundation Trust1 vizsgálat
- és még 16
Futó vizsgálatok
Fut, nem toboroz
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
In Vivo Dosimetry for Brachytherapy Study
NCT06863090· East and North Hertfordshire NHS Trust· Forrás
Contact: Rishma Bhatti
Fut, nem toboroz
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· 3. fázis· NovoCure GmbH· Forrás
Toboroz
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Personalized Medicine for Advanced Biliary Cancer Patients
NCT05615818· 3. fázis· UNICANCER· Forrás
Contact: Vasiliki MICHALAREA, MD
Toboroz
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· 3. fázis· Amgen· Forrás
Toboroz
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
NCT06295731· 2/3. fázis· Inhibrx Biosciences, Inc· Forrás
Contact: Study Director - Inhibrx
Toboroz
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· 3. fázis· Amgen· Forrás
Fut, nem toboroz
A Prospective Natural History Study in Uveal Melanoma
NCT04588662· Columbia University· Forrás
Fut, nem toboroz
Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus
NCT04046133· 1. fázis· Cardiff University· Forrás
Fut, nem toboroz
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247· OncoHost Ltd.· Forrás
Fut, nem toboroz
Avelumab Program Rollover Study
NCT03815643· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629· Prostate Cancer Clinical Trials Consortium· Forrás
Contact: Anand Sharma, MD
Toboroz
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
NCT03150576· 2/3. fázis· Cambridge University Hospitals NHS Foundation Trust· Forrás
Contact: Stephanie Sutherland (principal investigator)
Fut, nem toboroz
Study of Tumour Focused Radiotherapy for Bladder Cancer
NCT02447549· 2. fázis· Institute of Cancer Research, United Kingdom· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
NCT05198934· 3. fázis· Amgen· Forrás
Lezárult
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203· 3. fázis· AVEO Pharmaceuticals, Inc.· Forrás
Leállították
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
NCT04459715· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556· 1/2. fázis· Eisai Inc.· Forrás
Lezárult
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT03778931· 3. fázis· Stemline Therapeutics, Inc.· Forrás
Lezárult
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
NCT03648489· 2. fázis· Imperial College London· Forrás
Lezárult
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
NCT03371017· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
NCT03070392· 2. fázis· Immunocore Ltd· Forrás
Lezárult
Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
NCT03117933· 2. fázis· University of Oxford· Forrás
Hibát jelzek